Captrust Financial Advisors Alnylam Pharmaceuticals, Inc. Transaction History

Captrust Financial Advisors

$33 Billion
Q3 2024

A detailed history of Captrust Financial Advisors transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 4,833 shares of ALNY stock, worth $1.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,833

Previous 3,596 34.4%

Holding current value

$1.29 Million

Previous $873,000 52.23%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$233.81 - $287.01 $289,222 - $355,031	1,237 Added 34.4%	4,833 $1.33 Million
Q2 2024 Aug 14, 2024	SELL	$143.31 - $247.0 $6,162 - $10,621	-43 Reduced 1.18%	3,596 $873,000
Q1 2024 May 15, 2024	SELL	$146.51 - $198.2 $142,847 - $193,245	-975 Reduced 21.13%	3,639 $543,000
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $64,652 - $83,935	427 Added 10.2%	4,614 $883,000
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $125,345 - $155,351	-734 Reduced 14.92%	4,187 $741,000
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $506,187 - $580,168	2,736 Added 125.22%	4,921 $934,000
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $104,116 - $134,252	570 Added 35.29%	2,185 $437,000
Q4 2022 Feb 15, 2023	BUY	$185.53 - $241.31 $25,974 - $33,783	140 Added 9.49%	1,615 $383,000
Q3 2022 Nov 16, 2022	BUY	$138.54 - $232.0 $26,322 - $44,080	190 Added 14.79%	1,475 $295,000
Q2 2022 Aug 23, 2022	SELL	$120.42 - $169.29 $22,638 - $31,826	-188 Reduced 12.76%	1,285 $187,000
Q2 2022 Aug 16, 2022	BUY	$120.42 - $169.29 $29,021 - $40,798	241 Added 19.56%	1,473 $215,000
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $41,842 - $57,216	329 Added 36.43%	1,232 $201,000
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $7,978 - $10,464	50 Added 5.86%	903 $153,000
Q3 2021 Nov 16, 2021	BUY	$169.75 - $207.73 $25,632 - $31,367	151 Added 21.51%	853 $161,000
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $4,630 - $6,368	36 Added 5.41%	702 $119,000
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $63,795 - $88,372	503 Added 308.59%	666 $94,000
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $7,378 - $8,820	-60 Reduced 26.91%	163 $21,000
Q2 2020 Aug 14, 2020	BUY	$104.21 - $156.44 $23,238 - $34,886	223 New	223 $33,000
Q4 2019 Feb 14, 2020	SELL	$74.51 - $124.23 $65,792 - $109,695	-883 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $51,969 - $64,372	733 Added 488.67%	883 $71,000
Q3 2017 Feb 16, 2018	BUY	$72.53 - $118.27 $10,879 - $17,740	150	150 $18,000

Others Institutions Holding ALNY

# of Institutions

674

Shares Held

111M

Call Options Held

1.23M

Put Options Held

1.17M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $32.7B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Account

Captrust Financial Advisors Alnylam Pharmaceuticals, Inc. Transaction History